

**"Relevant" Adverse Events: Subjects**

<b>Table 1</b>		N =	42086	
Gender	F	29914	71%	
	M	9182	22%	
	ND	2990	7%	
	Total	42086		
Age	<12	34		
	<16	46		
	<= 17	95		
	18-30	4953		
	31-50	13886		
	51-64	7884		
	65-74	3098		
	>=75	5214		
	Ukn	6876		
	Total	42086		
Outcome		N =	42086	
*Of (total)-(unknown)	Recovered/Recovering*	19582	60%	
*Of (total)-(unknown)	Not recovered*	11361	35%	
Of 42,086	Unknown*	9400	22%	
	Fatal*	1223	4%	
Of (total)-(unknown)	Recovered with sequelae*	520	2%	
	N - Unknown =	32686		
<b>Estimated range in all cases not recovered after removing unknowns</b>		<b>Died or not Recovered</b>	<b>40-87%</b>	
Percent recovered to percent not recovered	Recovered e	NOT Recovered e		
9 to 1	17624	1958		
6 to 4	11749	7833		
5 to 5	9791	9791		
4 to 6	7833	11749		
1 to 9	4209	15373		
Recovered/Recovering Estimation Calculations	<b>Estimated Not Recovered + Died</b>	<b>Estimated percent not recovered</b>		
Fatal + Not recovered + Sequelae	13104	40%		
Fatal + NR + S + estimated recovering*	15062	46%		
* Scaled estimated Recovering	20937	64%		
	22895	70%		
	24853	76%		
	28477	87%		

Cumulative Analysis of Post-authorization Adverse Events Through 2/28/2021

Tables 1-6 AES

<b>Table 1 Disorders &gt;= 2%</b>			
	<b>WHERE IS THIS DATA?</b>		
General and admin site	<b>51335</b>	122%	Compare with 42086
Nervous System	<b>25957</b>	62%	
MS & Connective Tissue	<b>17283</b>	41%	
GI	<b>14096</b>	33%	
Resp, Thoracic, and Mediastinal	<b>8848</b>	21%	
Skin and SubCu	<b>8476</b>	20%	
<b>Injury, poisoning, and procedural</b>	<b>5590</b>	13%	<b>WHERE IS THIS TOXICITY DATA?</b>
Covid-19	<b>1927</b>	5%	
<b>Investigations</b>	<b>3693</b>	<b>9%</b>	<b>????</b>
<b>Total</b>	<b>137205</b>	<b>93473</b>	<b>????</b>
<b>Table 2 Events &gt;=2% Cases</b>			
		N = 42086	
	Blood and lymphatic	1972	4.69%
	Cardiac Table 2	1098	"Tachycardia"
	Cardiac Table 7	1403	Table 2 + 7
	<b>Auto immune Myocarditis</b>	25	
	<b>Auto immune Pericarditis</b>	32	
	Total Cardiac	1460	3.47%
	GI	8760	20.81%
	General and admin site	39451	93.74%
<b>See total from Table 7</b>	<b>COVID19</b>	<b>1927</b>	<b>4.58%</b>
<b>Total procedural errors</b>	<b>Procedural complications</b>	<b>1708</b>	<b>4.06%</b>
<b>3416</b>	<b>Off label use</b>	<b>880</b>	<b>2.09%</b>
	<b>Product use issue</b>	<b>828</b>	<b>1.97%</b>
	Musculoskeletal & CT	12399	29.46%
	Nervous system	16350	38.85%
	Respiratory, Thoracic, Mediastinal	4151	9.86%
	Skin and SubQ	5657	13.44%
	<b>Total number of events</b>	<b>93473</b>	<b>2.2 per subject</b>

**Table 3-5 Safety Concerns**

	Cases	
<b>Anaphylaxis BC1-4</b>	<b>1002</b>	<b>4 patients died on the same day the injection was given</b>
Potential Anaphylaxis Cases	2958	9.4%
Vaccine Enhanced Disease	138	317 events
Use in Pregnancy and Lactation	413	84 S/329 NS
<b>Pregnancy outcomes</b>	N = 270	
<b>No Outcome</b>	<b>238</b>	<b>88%</b>
Outcome Pending	5	
<b>Known outcome</b>	<b>27</b>	
<b>Spontaneous abortions</b>	<b>23</b>	<b>85%</b>
Premature birth neonatal death	2	7%
Spontaneous abortion intrauterine death	2	7%
Spontaneous abortion neonatal death	1	4%
<b><u>Normal outcome</u></b>	<b><u>1</u></b>	<b><u>4%</u></b>
<b>Mother cases</b>	124	
Spontaneous abortion	25	20%
Myalgia	16	13%
Pyrexia	16	13%
Lymphadenopathy	7	6%
Chest pain	6	5%
Dizziness	6	5%
Asthenia	6	5%
Malaise	5	4%
Covid-19	5	4%
Uterine contraction	1	1%
Premature membrane rupture	1	1%
Abortion	1	1%
Abortion missed	1	1%
Fetal death	1	1%


<b>Serious foetus/baby cases</b>	4	
Fetal growth restriction/premature baby	2 each	
Neonatal death	1	
<b>Breast feeding baby cases</b>	133	
No adverse events	116	87%
Breast feeding infant child reactions	17	13%
Of those with Aes		
Fever	5	29%
Rash	4	24%
Irritability	3	18%
Vomiting	2	12%
Diarrhea	2	12%
Insomnia	2	12%
Illness	2	12%
Poor feeding	1	6%
Lethargy	1	6%
Abdominal discomfort	1	6%
Vomiting	1	6%
Allergy to vaccine	1	6%
Increased appetite	1	6%
Anxiety	1	6%
Crying	1	6%
Poor quality sleep	1	6%
Eructation	1	6%
Agitation	1	6%
Pain	1	6%
Urticaria	1	6%
<b>Breast feeding mother cases</b>	6	
Chills, malaise, and pyrexia	1	
Suppressed lactation	4	
Unknwn AE	1	
Breast milk discoloration	1	

Cumulative Analysis of Post-authorization Adverse Events Through 2/28/2021

Tables 1-6 AES

<b>Pediatric age &lt;12</b>	<b>34</b>	<b>132 AEs</b>	
<b>Age range (Youngest 28 days not 2 months)</b>	<b>2 mos. To 9 years</b>	<b>3.7 years average</b>	
Serious	24	71%	
Non-serious	10	29%	
Product administered to Pt of inappropriate age	27	<b>1 seven year old had a stroke</b>	
Off label use	11		
Pyrexia	6		
Product use issue	5		
Fatigue	4		
Headache	4		
Nausea	4		
Injection site pain	3		
Abdominal pain	2		
COVID-19	2		
Facial paralysis	2		
Lymphadenopathy	2		
Malaise	2		
Pruritis	2		
Swelling	2		
<b>"Vaccine" effectiveness</b>	<b>Table 6</b>		
Failure	19	7 days after two doses	Confirmed C19
"Vaccine" ineffective	1649	Unknown: 2 doses?, # days since 1st dose, unk. Time since 2nd.	Suspected C19
COVID-19	3067		
Outcome unknown	1230	74%	
Fatality	65	15%	

**From Table 7 Analysis**



**Covid is the leading adverse event  
after arthralgia and fever**

### 5.3.6 Cumulative Analysis of Post Authorization Adverse Event Reports Through 2/28/2021

Table 7: Adverse Events of Special Interest

<b>"Relevant" Adverse Events: Subjects</b>		N = 42086	
<b>Autoimmune (# and % of AEs)</b>	<b>1155</b>		<b>3%</b>
<b>Gender</b>	<b>838</b>		
Female	682		
Male	156		
<b>Age</b>	<b>944</b>		
12-17	2		
18-64	746		
>=65	196		
<b>Diagnoses</b>	<b>855</b>		
Hypersensitivity	596		
Arthritis*	70		<b>*From Musculoskeletal</b>
Peripheral neuropathy	49		
Rheumatoid arthritis*	26		<b>*From Musculoskeletal</b>
Dermatitis	24		
Encephalitis	16		
Diabetes	16		
Psoriasis	14		
Bullous dermatitis	13		
Autoimmune disorder	11		
Reynaud's phenomena	11		
Polyarthritis*	5		<b>*From Musculoskeletal</b>
Polyneuropathy*	4		<b>*From Musculoskeletal</b>
<b>Outcome</b>	<b>1078</b>		
Other	517		
<b>Unknown</b>	<b>312</b>		<b>28.9%</b>
Not resolved	215		
Resolved with sequelae	<b>22</b>		<b>2.0%</b>
<b>Fatal</b>	<b>12</b>		<b>1.1%</b>

### 5.3.6 Cumulative Analysis of Post Authorization Adverse Event Reports Through 2/28/2021

Table 7: Adverse Events of Special Interest

AEs		N = 42086	
<b>Cardiac (# and % of AEs)</b>	<b>1460</b>		<b>3.5%</b>
Gender	<b>1403</b>		
Female	1076		
Male	291		
Unknown	36		
Age	<b>1346</b>		
<b>2-11</b>	<b>1</b>		
<b>12-17</b>	<b>1</b>		
<b>18-64</b>	<b>1078</b>		
>= 65	266		
Diagnoses	<b>1498</b>		
<b>Arrythmia<sup>1</sup></b>	1200		
Myocardial Infarction	130		
Cardiac Failure	91		
<b>Pericarditis*</b>	<b>32</b>		<b>From Autoimmune</b>
<b>Myocarditis*</b>	<b>25</b>		<b>From Autoimmune</b>
Cardiogenic shock	7		
Postural orthostatic tachycardia syndrome	7		
Coronary artery disease	6		
<sup>1</sup> 7666 subjects had "pyrexia". Fever is accompanied by elevation in heart rate 10 beats/min for females per degree C and 7 b/m for males per degree C.		Assuming tachycardia listed in Table 7 refers to SVT etc.	
Outcome	<b>1444</b>		
Other	767		
<b>Unknown</b>	<b>380</b>		<b>26.0%</b>
Not resolved	140		
<b>Fatal*</b>	<b>136</b>		<b>9.3%</b>
Resolved with Sequelae	21		
<b>*May not include Myopericarditis fatalities</b>			



## 5.3.6 Cumulative Analysis of Post Authorization Adverse Event Reports Through 2/28/2021

Table 7: Adverse Events of Special Interest

	AEs	N = 42086
<b>COVID-19 (# and % of total AEs)</b>	<b>3067</b>	<b>7.3%</b>
Gender	<b>3067</b>	
Female	1650	
Male	844	
Unknown	573	
<b>Age</b>	<b>1880</b>	
<b>Infant*</b>	<b>2</b>	<b>*28 days to 27 mos.</b>
<b>2-11</b>	<b>1</b>	
<b>12-17</b>	<b>2</b>	
18-64	1315	
>= 65	560	
Diagnoses	<b>3356</b>	
COVID-19	1927	
SC2 test +	415	
Suspected C19	270	
Ageusia	228	
Anosmia	194	
SC2 Antibody test negative	83	
Exposure to SC2	62	
SC 2 Antibody test positive	53	
C 19 pneumonia	51	
Asymptomatic C19	31	
Coronavirus infection	13	
Occupational exposure SC2	11	
SC2 false positive test	7	
SC2 test positive	6	
SC 2 test negative	3	
SC 2 antibody test negative	2	
Outcome	<b>3360</b>	
<b>Unknown</b>	<b>2110</b>	<b>62.8%</b>
Other	558	
<b>Fatal</b>	<b>136</b>	<b>4.0%</b>
Resolved with sequelae	9	
Not resolved	547	

### 5.3.6 Cumulative Analysis of Post Authorization Adverse Event Reports Through 2/28/2021

Table 7: Adverse Events of Special Interest

	AEs	N= 42086	
<b>Dermatological (# and % of total AEs)</b>	<b>20</b>		0.05%
Gender	19		
Female	17		
Male	1		
Unknown	1		
Age	19		
<b>Infant</b>	0		
<b>2-11</b>	0		
<b>12-17</b>	0		
18-64	18		
>= 65	1		
Diagnoses	20		
Erythema multiforme	13		
Vasculitis	7		
Outcome	21		
Not resolved	8		
Other	7		
<b>Unknown</b>	<b>6</b>		<b>29%</b>

## 5.3.6 Cumulative Analysis of Post Authorization Adverse Event Reports Through 2/28/2021

Table 7: Adverse Events of Special Interest

	AEs	N = 42086
<b>Hematological (# and % of Total AEs)</b>	<b>932</b>	
Gender	898	<b>Bleeding</b>
Female	676	<b>731</b>
Male	222	<b>87%</b>
Unknown	N/A	
Age	<b>837</b>	
<b>Infant</b>	1	
<b>2-11</b>	0	
<b>12-17</b>	0	
18-64	543	
>= 65	293	
Diagnoses	888	
Epistaxis	127	
Contusion	112	
Site bruising	96	
Site hemorrhage	51	
Petechia	50	
Hemorrhage	42	
Hematochezia	34	
Thrombocytopenia	33	
Site hematoma	32	
Conjunctival hemorrhage	29	
Vaginal bleeding	29	
Hematoma	27	
Hemoptysis	27	
Menorrhagia	27	
Hematemesis	25	
Eye hemorrhage	23	
Rectal hemorrhage	22	
Immune thrombocytopenia	20	
Hematuria	35	
Neutropenia	16	
Purpura	16	
Hemorrhagic diarrhea	15	
Outcome	<b>1082</b>	
Other	393	
<b>Unknown</b>	<b>371</b>	<b>34%</b>
Not resolved	267	
<b>Fatal</b>	<b>34</b>	<b>3.1%</b>
Resolved with sequelae	17	

## 5.3.6 Cumulative Analysis of Post Authorization Adverse Event Reports Through 2/28/2021

Table 7: Adverse Events of Special Interest

	AEs	N = 42086
<b>Hepatic (# and % of Total AEs)</b>	<b>70</b>	
Gender	<b>70</b>	
Female	43	
Male	26	
Unknown	1	
Age	<b>64</b>	
<b>Infant</b>	0	
<b>2-11</b>	0	
<b>12-17</b>	0	
18-64	37	
>= 65	27	
Diagnoses	82	
LFTs elevated	70	
Hepatic pain	9	
Ascities	3	
Outcome	<b>94</b>	
<b>Unknown</b>	<b>47</b>	
Other	27	
Not resolved	14	
<b>Fatal</b>	<b>5</b>	
Resolved with sequelae	1	
	AEs	N = 42086
<b>Musculoskeletal (# and % of total AEs)</b>	3495	<b>(-)Arthritis/polyneuropathy</b>
Gender	3471	
Female	2760	
Male	711	
Age	3372	
<b>Infant</b>	<b>1</b>	
<b>2-11</b>	<b>4</b>	
Arthralgia	<b>2</b>	
18-64	2850	
>= 65	515	
Diagnoses	3534	
Arthralgia	3525	
Post viral fatigue syndrome	4	
Chronic fatigue syndrome	4	
Bacterial arthritis	1	
Outcome	3662	
Other	1801	
Not resolved	959	
Unknown	853	
Resolved with sequelae	49	

### 5.3.6 Cumulative Analysis of Post Authorization Adverse Event Reports Through 2/28/2021

Table 7: Adverse Events of Special Interest

	AEs	N= 42086
<b>Neurological AESIs (# and % of total AEs)</b>	<b>950</b>	
Gender	927	
Female	623	
Male	283	
Unknown	21	
Age	889	
<b>Infant</b>	<b>1</b>	VIIth nerve palsy
<b>2-11</b>	<b>1</b>	
12-17	0	
18-64	642	
>= 65	245	
<b>Diagnoses</b>		
<b>Facial paralysis</b>	<b>401</b>	<b>Facial Nerve Injury =</b>
Seizure	204	<b>492</b>
Epilepsy	83	<b>Seizure =</b>
<b>Facial paresis</b>	<b>64</b>	<b>404</b>
Generalized seizure	33	<b>Demyelinating =</b>
Guillain-Barre syndrome	24	<b>28</b>
Fibromyalgia	17	<b>GB =</b>
<b>Trigeminal neuralgia</b>	<b>17</b>	<b>24</b>
Febrile convulsion	15	
Status epilepticus	12	
Aura (petit mal?)	11	
Transverse myelitis	11	
Multiple sclerosis relapse	10	
Optic neuritis	10	
Petit mal epilepsy	9	
Tonic convulsion	9	
Ataxia	8	
Encephalopathy	7	
Tonic clonic movements	7	
Foaming at mouth	5	
Polyneuropathy	4	
Multiple sclerosis	4	
Narcolepsy	4	
Partial seizures	4	
Bad sensation	3	
Demyelination	3	
Meningitis	3	
Post ictal state	3	
Seizure like phenomena	3	
Tongue biting	3	
Outcome	<b>1011</b>	
Other	449	
Not resolved	272	
<b>Unknown</b>	<b>258</b>	
<b>Fatal</b>	<b>16</b>	
Resolved with sequelae	16	

## 5.3.6 Cumulative Analysis of Post Authorization Adverse Event Reports Through 2/28/2021

Table 7: Adverse Events of Special Interest

	AEs	N= 42086
<b>Other AESIs (# and % of total ASEs)</b>	<b>8152</b>	
Gender	7829	
Female	5969	
Male	1860	
Unknown	N/A	
Age	7479	
<b>Infant</b>	6	
<b>2-11</b>	9	
12-17	9	
18-64	6330	
>= 65	1125	
Diagnoses	8207	<b>Fever = 94% of category.</b>
Pyrexia	7666	<b>Herpes 391 cases</b>
Herpes zoster (shingles)	259	
Inflammation	132	
Oral herpes	80	
Multiple organ dysfunction synd.	18	
Herpes virus infection	17	
Herpes simplex	13	
Ophthalmic herpes	10	
Herpes ophthalmic	6	
Herpes zoster reactivation	6	
Outcome	8218	
Other	5008	
<b>Unknown</b>	<b>1685</b>	<b>21%</b>
Not resolved	1429	
<b>Fatal</b>	<b>96</b>	<b>1%</b>

## 5.3.6 Cumulative Analysis of Post Authorization Adverse Event Reports Through 2/28/2021

Table 7: Adverse Events of Special Interest

	AEs	N= 42086
<b>Renal AESIs (# and % of total ASEs)</b>	69	
Gender	69	
Female	46	
Male	23	
Unknown	N/A	
Age		
<b>Infant</b>	1	
<b>2-11</b>	0	
12-17	0	
18-64	7	
>= 65	60	
Diagnoses		
Acute kidney injury	40	
Renal failure	30	
Outcome	<b>70</b>	
<b>Fatal</b>	<b>23</b>	<b>33%</b>
<b>Unknown</b>	<b>22</b>	<b>32%</b>
Not resolved	15	
Other	10	
	AEs	N= 42086
<b>Respiratory AESIs</b>	<b>130</b>	
Gender	130	
Female	72	
Male	58	
Unknown	N/A	
Age	<b>126</b>	
<b>Infant</b>	0	
<b>2-11</b>	0	
12-17	1	
18-64	47	
>= 65	78	
Diagnoses	<b>137</b>	
Respiratory failure	44	
Hypoxia	42	
Respiratory disorder	36	
ARDS	10	
Chronic respiratory syndrome	3	
Severe acute respiratory syndrome	2	
Outcome	137	
Other	47	
<b>Fatal</b>	<b>41</b>	<b>32%</b>
<b>Unknown</b>	<b>31</b>	<b>24%</b>
Not recovered	18	

## 5.3.6 Cumulative Analysis of Post Authorization Adverse Event Reports Through 2/28/2021

Table 7: Adverse Events of Special Interest

	AEs	N= 42086
<b>Stroke AESIs (# and % of total ASEs)</b>	<b>275</b>	
Gender	<b>273</b>	
Female	182	
Male	91	
Unknown	N/A	
Age	<b>265</b>	
<b>Infant</b>	0	
<b>2-11</b>	1	
12-17	0	
18-64	59	
>= 65	205	
<b>Diagnoses</b>	<b>292</b>	
<b>Ischemic</b>	<b>237</b>	<b>81%</b>
Cerebrovascular accident	160	
Ischemic stroke	41	
Cerebral infarction	15	
Cerebral ischemia	3	
Cerebral thrombosis	3	
Cerebral venous sinus thrombosis	3	
Ischemic cerebral infarction	3	
Lacunal infarction	3	
Basal ganglia stroke	2	
Cerebellar infarction	2	
Thrombotic stroke	2	
<b>Hemorrhagic</b>	<b>55</b>	<b>19%</b>
Cerebral hemorrhage	26	
Hemorrhagic stroke	11	
Hemorrhage intercranial	5	
Subarachnoid hemorrhage	5	
Cerebral hematoma	4	
Basal ganglia hemorrhage	2	
Cerebellar infarction	2	
Outcome	<b>300</b>	
Not resolved	85	
<b>Unknown</b>	<b>83</b>	<b>28%</b>
<b>Fatal</b>	<b>61</b>	<b>20%</b>
Other	61	
Resolved with sequelae	10	



## 5.3.6 Cumulative Analysis of Post Authorization Adverse Event Reports Through 2/28/2021

Table 7: Adverse Events of Special Interest


	AEs	N= 42086
<b>Thromboembolic event (# and % of total ASEs)</b>	<b>151</b>	
Gender	<b>144</b>	
Female	89	
Male	55	
Unknown	N/A	
Age	<b>136</b>	
<b>Infant</b>	0	
<b>2-11</b>	0	
12-17	0	
18-64	66	
>= 65	70	
<b>Diagnoses</b>	<b>151</b>	
Pulmonary embolism	60	
Thrombosis	39	
DVT	35	
Thrombophlebitis peripheral	6	
Venous thrombosis	4	
Embolism	3	
Microembolism	3	
Thrombophlebitis	3	
Venous thrombosis	3	
Blue toe syndrome	2	
Outcome	<b>169</b>	
Other	54	
Not resolved	49	
<b>Unknown</b>	<b>42</b>	<b>25%</b>
<b>Fatal</b>	<b>18</b>	<b>11%</b>
Resolved with sequelae	6	

### 5.3.6 Cumulative Analysis of Post Authorization Adverse Event Reports Through 2/28/2021

Table 7: Adverse Events of Special Interest


	AEs	N= 42086
<b>Vasculitis (# and % of total AEs)</b>	<b>32</b>	
Gender	32	
Female	26	
Male	6	
Unknown	N/A	
Age	31	
<b>Infant</b>	0	
<b>2-11</b>	0	
12-17	0	
18-64	15	
>= 65	16	
<b>Diagnoses</b>	<b>32</b>	
Vasculitis	14	
Cutaneous vasculitis	4	
Vasculitic rash	4	
Giant cell arteritis	3	
Peripheral ischemia	3	
Bechet's syndrome	2	
Hypersensitivity vasculitis	2	
Palpable purpura	1	
Takayasu's arteritis	1	
Outcome	<b>34</b>	
Other	13	
Not resolved	12	
<b>Unknown</b>	<b>8</b>	<b>24%</b>
<b>Fatal</b>	<b>1</b>	<b>3%</b>

### 5.3.6 Adverse Events of Special Interest AEIs by Organ System



Category*	N =
Other	8152
Musculoskeletal	3495
Covid-19	3067
Cardiac	1460
Autoimmune	1155
Neurologic	950
Hematologic	932
Stroke	275
Thromboembolic	151
Respiratory (Covid?)	130
Hepatic	70
Renal	69
Vasculitis	32
Dermatological	20
	19958

### 5.3.6 Adverse Events of Special Interest AESIs by Organ System





Category	% Fatality	% Unknown	# Unknown	Outcome
Respiratory (Covid?)	33	31%	22	70
Renal	33	31%	22	70
Stroke	20	28%	83	300
Thromboembolic	11	25%	42	169
Cardiac	9.3	26%	380	1444
Hepatic	5.3	52%	47	90
Covid-19	4	63%	2110	3360
Hematologic	3.1	34%	371	1082
Neurologic	3	30%	161	544
Vasculitis	2.9	24%	8	34
Autoimmune	1.1	29%	312	1078
Dermatological	0	29%	6	21
Musculoskeletal	0	30%	853	2809
Other	0%	26%	1685	6533
<b>Totals</b>			<b>6102</b>	<b>17604</b>
<b>AESI Outcome</b>	<b>% Unknown outcome</b>	<b>31%</b>		

### 5.3.6 Adverse Events of Special Interest AESIs by Organ System

<b>AESI Fatalities</b>			
<b>Category*</b>	<b>N =</b>	<b>Fatalities</b>	<b>Percent Fatal</b>
Cardiac	1460	136	9%
Covid-19	3067	136	4%
Other	8152	96	1%
Stroke	275	61	22%
Respiratory (Covid?)	130	41	32%
Hematologic	932	34	4%
Renal	69	23	33%
Thromboembolic	151	18	12%
Neurologic	950	16	2%
Autoimmune	1155	12	1%
Hepatic	70	5	7%
Vasculitis	32	1	3%
Dermatological	20	0	0%
Musculoskeletal	3495	0	0%
<b>Totals</b>	<b>19958</b>	<b>579</b>	<b>3%</b>

Table 1 Fatalities	1223
Fatalities accounted for	579
Missing	644
Missing %	53%

<b>AEs + AESIs</b>	<b>Cases not reported or lost</b>	
Table 1	"Relevant cases" per Pfizer	42086
Table 7	Organ systems	19958
Table 1	Outcome Unknown	9400
	Known Outcome	29358
	<b>"Missing"</b>	<b>12728</b>
		<b>30%</b>





**Neurologic**

Cranial nerve injury	492
Seizure	412

Selected Organ System Detail  
Pfizer Document 5.6.3

Demyelination	28
Guillain-Barre	24
Encephalopathy	7
Peripheral neuropathy	4
Meningitis	3
	970





Stroke	275
Thrombosis	152
Embolism	66